Last reviewed · How we verify
Zyloprim® 300 mg — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Zyloprim® 300 mg (Zyloprim® 300 mg) — Ardea Biosciences, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Zyloprim® 300 mg TARGET | Zyloprim® 300 mg | Ardea Biosciences, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Zyloprim® 300 mg CI watch — RSS
- Zyloprim® 300 mg CI watch — Atom
- Zyloprim® 300 mg CI watch — JSON
- Zyloprim® 300 mg alone — RSS
Cite this brief
Drug Landscape (2026). Zyloprim® 300 mg — Competitive Intelligence Brief. https://druglandscape.com/ci/zyloprim-300-mg. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab